These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

335 related items for PubMed ID: 6531660

  • 1. Effect of omeprazole, a substituted benzimidazole, on 24-h intragastric acidity in patients with peptic ulcer disease.
    Naesdal J, Bodemar G, Walan A.
    Scand J Gastroenterol; 1984 Oct; 19(7):916-22. PubMed ID: 6531660
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Efficacy of omeprazole one year after cure of Helicobacter pylori infection in duodenal ulcer patients.
    Labenz J, Tillenburg B, Peitz U, Börsch G, Idström JP, Verdú E, Stolte M, Blum AL.
    Am J Gastroenterol; 1997 Apr; 92(4):576-81. PubMed ID: 9128302
    [Abstract] [Full Text] [Related]

  • 5. Do anticholinergics interact with histamine H2 receptor antagonists on night intragastric acidity in active duodenal ulcer patients?
    Fiorucci S, Clausi GG, Farinelli M, Santucci L, Farroni F, Pelli MA, Morelli A.
    Am J Gastroenterol; 1988 Dec; 83(12):1371-5. PubMed ID: 2904218
    [Abstract] [Full Text] [Related]

  • 6. [Circadian monitoring of intragastric pH in evaluation of efficiency of antisecretory therapy of duodenal ulcer].
    Kolesnikova IIu, Beliaeva GS, Bordin DS.
    Klin Med (Mosk); 2002 Dec; 80(2):54-6. PubMed ID: 11898725
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Can optimal acid suppression prevent rebleeding in peptic ulcer patients with a non-bleeding visible vessel: a preliminary report of a randomized comparative study.
    Lin HJ, Lo WC, Perng CL, Wang K, Lee FY.
    Hepatogastroenterology; 1997 Dec; 44(17):1495-9. PubMed ID: 9356879
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Treatment of acid-peptic diseases by inhibition of gastric H+,K+-ATPase.
    McArthur KE, Jensen RT, Gardner JD.
    Annu Rev Med; 1986 Dec; 37():97-105. PubMed ID: 3010811
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity.
    Sharma BK, Walt RP, Pounder RE, Gomes MD, Wood EC, Logan LH.
    Gut; 1984 Sep; 25(9):957-64. PubMed ID: 6469081
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Persistent acid secretion during omeprazole therapy: a study of gastric acid profiles in patients demonstrating failure of omeprazole therapy.
    Leite LP, Johnston BT, Just RJ, Castell DO.
    Am J Gastroenterol; 1996 Aug; 91(8):1527-31. PubMed ID: 8759655
    [Abstract] [Full Text] [Related]

  • 18. [Omeprazole in peptic ulceration: acid inhibition and endoscopic healing].
    Chen SP, Mai CR, Ke MY.
    Zhonghua Nei Ke Za Zhi; 1989 Dec; 28(12):720-1, 767. PubMed ID: 2636088
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.